Objectives:The role of miR-106b and its target gene DAB2 (disabled-2) on the migration of cervical cancer cells
was explored.
The mRNA expression of miR-106b and DAB2 in cervical samples was detected using real time
quantitative PCR. The protein expression of DAB2 was examined by Western blot. Dual luciferase reporter
assay was used to identification of DAB2 as a miR-106b-directed target gene. Scratch and transwell assay were
used to determine the effects of miR-106b and DAB2 on the migration of Hela cells.
The expression level of miR-106b was clearly up-regulated in cervical cancer tissues. On the contrary,
DAB2 expression was decreased in cervical cancer specimens. Dual luciferase reporter assay showed that the
relative luciferase activity of WT-DAB2-3'UTR decreased approximately 30% after overexpression of miR-106b
in HEK293T cells, the results of Mut-DAB2-3'UTR had no difference compared with the control group. DAB2
was identified as a miR-106b-directed target gene. Overexpression of miR-106b in Hela cells significantly
promoted cell migration compared with the control group (P<0.05). However, inhibition of DAB2 with siRNA,
the rate of migration was increased remarkably (P<0.05).
miR-106b promotes the migration of cervical cancer cells by directly targeting DAB2. These data
suggested that miR-106b and DAB2 could play an important role in the pathogenesis of cervical carcinoma, and
miR-106b may be as a candidate of biomarker and a potential therapeutic target in cervical cancer.